Prespecified 3-year interim analysis of an RCT of aflibercept 0.4 mg vs laser for retinopathy of prematurity (100 children, 90 analysed): most had no ROP or unfavourable structural outcomes (98.3% and 93.9% vs 96.7% and 94.1%); high myopia 8.9% vs 24.1% of eyes.
RCTn = 100
Stahl et al. Three-Year Outcomes of Intravitreal Aflibercept versus Laser Therapy for Retinopathy of Prematurity: Interim Analysis of the Efficacy and Safety Outcomes in the FIREFLEYE next Trial